Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Mobile cardiac diagnostic device, 9/13

Samsung Electronics presented details of the first peer-reviewed report of a pilot conducted with the National Health Service in Scotland, Borders General Hospital, the Scottish Ambulance Service, and the Scottish Centre for Telehealth and Telecare on the use of the company’s Labgeo IB10 portable blood analyzer to diagnose cardiac patients in transit to the hospital. Conducted in the sparsely populated Scottish Borders, the pilot sought to demonstrate the feasibility of diagnosing whether chest pain patients were suffering from a heart

Tuberculosis test, 9/13

Cepheid has received FDA market authorization for its Xpert MTB/RIF test, which provides results in about two hours. The review decision was based on the de novo 510(k) review process, which allows novel products without predicates to be downclassified and brought to market. Xpert MTB/RIF is for the rapid molecular detection of Mycobacterium tuberculosis complex (MTB-complex) DNA and, in specimens where MTB-complex DNA is detected, Xpert MTB/RIF also detects rifampin-resistant associated mutations of the rpoB gene. Designed for use on

HIV-1 test added to mPlus menu, 9/13

September 2013—Abbott has received FDA approval to expand the use of its RealTime HIV-1 assay to run on the company’s mPlus system. In April, Abbott introduced mPlus capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient for laboratories.

Troponin assay, 9/13

AACC 2013 Abbott announced results from a study evaluating its high sensitive troponin-I (hsTnI) assay. The study, conducted by researchers at Brigham and Women’s Hospital, demonstrated that Abbott’s Architect stat hsTnI test may help doctors predict which patients presenting with symptoms of a heart attack are at a higher risk for having a heart attack 30 days after presentation. Researchers at Brigham and Women’s evaluated the performance of Abbott’s Architect stat hsTnI assay with the performance of a fourth-generation troponin

Incubators, 9/13

Eppendorf North America offers a new generation of its ThermoMixer and ThermoStat incubators. The excellent mixing results of the ThermoMixer C, F1.5 and FP (two-in-one instruments for combined mixing and incubating) are due to the company’s two-dimensional mix-control technology, which ensures fast and efficient mixing in seconds. Through controlled circular movements, liquids in small volumes are thoroughly mixed, while anti-spill technology prevents lid wetting and cross-contamination. For dry incubation, the company’s ThermoMixer C and ThermoStat C operate together with SmartBlocks,

Extended mutation detection technology, 9/13

Seegene has launched its multiple mutation detection technology to accelerate the development of companion diagnostic tests. The technology transforms conventional real-time instruments into powerful systems to simultaneously detect multiple mutation targets in a single channel. Seegene has extended the capabilities of its real-time PCR technology to simultaneously detect more than 20 different mutations, including insertions, deletions, and point mutations, in a single tube and single reaction. The technology detects minority mutation or species when wild-type is in excess of 10,000-fold

Safety device for blood draws, 9/13

Greiner Bio-One’s Vacuette Tube-Touch passive safety device has a passive safety shield that activates upon tube insertion, reducing the risk of exposure to bloodborne pathogens from a needlestick. The product comes to the customer completely assembled with a needle, safety shield, and tube holder. Greiner Bio-One, 888-286-3883

HbA1c control, 9/13

Streck’s A1c-Cellular Linearity, an HbA1c linearity/calibration verification material with intact red blood cells, is now assayed for Roche Diagnostics’ Cobas c 311. It is a five-level assayed linearity material used to assess instrument accuracy and verify the patient reportable range of the HbA1c parameter. The product does not require reconstitution, which reduces the potential for human errors and saves time. The linearity material tests the entire reportable range of the instrument system, including the lyse step. Instrument-specific target values and

App for preventing preanalytical errors in blood gas testing, 9/13

Radiometer America offers its “Avoid Errors” application for the iPhone. The app allows users to identify typical preanalytical errors in blood gas testing. The content of the “Avoid Errors” application is threefold, with tips on how to prevent errors, a troubleshooting section, and a skill test. A handbook section in the app contains videos that show how to properly collect a blood gas sample by arterial puncture, through an arterial line, or by capillary sampling. The handbook also describes several

Immunoanalyzer licensed for clinical use in Canada, 10/13

Wako Diagnostics was issued three class III medical device licenses by Health Canada to market the uTAS-Wako i30 instrument with the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma.

MARKETPLACE

TRENDING